Menu Search
Equities

Co-Diagnostics Inc

0A50:LSE

Co-Diagnostics Inc

Actions
  • Price (USD)1.26
  • Today's Change-0.034 / -2.65%
  • Shares traded127.00
  • 1 Year change+21.63%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 17:37 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.

  • Revenue in USD (TTM)9.14m
  • Net income in USD-37.57m
  • Incorporated2013
  • Employees155.00
  • Location
    Co-Diagnostics Inc4049 S Highland DrSALT LAKE CITY 84124-1664United StatesUSA
  • Phone+1 (801) 278-9769
  • Websitehttp://codiagnostics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.